



EDF1

a





b




a

	SARS-CoV-2 negative		SARS-CoV-2 positive	
	Children	Adults	Children	Adults
MC_Basophil	[0.25]	[0.18]	[0.15]	[0.57]
Neutrophil	[22.14***]	[0.28]	[6.04]	[3.01]
mDC	[2.66**]	[0.85]	[1.99]	[1.72]
CD11c_mDC	[0.49]	[0.4]	[1.63]	[1.28]
pDC	[0.48]	[0.2]	[1.51]	[0.95]
rMa	[5.66**]	[1.47]	[6.74]	[6.93]
nrMa	[0.41]	[0.23]	[2.14]	[1.76]
moMa	[0.78]	[0.4]	[5.22]	[4.88]
NK	[0.48**]	[0.09]	[1.16]	[0.93]
p_NKT	[0.06*]	[0.0]	[0.15]	[0.1]
p_T	[0.72]	[1.06]	[1.25]	[1.09]
ag_T	[1.01***]	[0.18]	[1.8]	[1.79]
Treg	[0.73**]	[0.18]	[0.99]	[0.98]
DNT	[3.32***]	[0.56]	[2.79]	[2.13]
CD8_Tm	[1.21***]	[0.09]	[2.01]	[0.84]
IL17A_CD8	[1.85 ***]	[0.36]	[1.89]	[1.66]
IL17A_CD4	[1.08 **]	[0.4]	[1.27]	[1.47]
CTL2	[3.31***]	[0.37]	[3.49]	[2.88]
CTL1	[2.48**]	[0.76]	[2.85]	[3.71]
Plasma_cell	[1.45***]	[0.1]	[0.8]	[0.42]
B_cell	[1.18 **]	[0.23]	[1.44]	[1.53]
immune_total	[51.74***]	[8.41]	[47.32]	[40.62]
lowRNA	[2.58]	[2.14]	[2.24]	[1.35]
Epi_lowRNA	[9.31]	[11.44]	[8.89]	[8.43]
Squamous	[2.18]	[6.39]	[1.8]	[4.93]
Ionocyte	[0.51]	[0.66]	[1.07]	[0.82]
FOXN4	[0.66]	[0.63]	[0.81]	[0.51]
Basal	[0.68***]	[7.15]	[0.64]	[1.07]
Cil_diff	[1.74 **]	[4.71]	[4.08]	[5.11]
Cil_acute_phase	[1.87 ***]	[10.26]	[5.87]	[8.12]
Ciliated	[2.4 ***]	[20.59]	[6.79]	[11.85]
Sec_diff	[4.09**]	[7.8]	[3.5]	[3.88]
Goblet	[16.89]	[11.94]	[12.71]	[9.59]
Club	[5.35]	[7.85]	[4.27]	[3.72]

b



EDF4



Supplementary Table 1: Characteristics of the **(a)** positive (n = 45) and **(b)** negative (n = 42) individuals included in the here present study.

(a)

Patient-ID	Gender	Age (years)	SARS-CoV-2	WHO	Sampling dps*	Sampling dpP#
BIH-c-CoV-01	f	< 1 year	positive	mild	8	0
BIH-c-CoV-02	m	< 1 year	positive	mild	3	3
BIH-c-CoV-03	m	1-5	positive	asymptomatic	no symptoms	2
BIH-c-CoV-04	f	6-10	positive	mild	1	1
BIH-c-CoV-05	m	6-10	positive	mild	11	6
BIH-c-CoV-06	m	6-10	positive	mild	1	0
BIH-c-CoV-07	f	6-10	positive	moderate	7	0
BIH-c-CoV-08	m	6-10	positive	mild	4	1
BIH-c-CoV-09	m	6-10	positive	mild	6	0
BIH-c-CoV-10	f	11-15	positive	asymptomatic	no symptoms	0
BIH-c-CoV-11	m	11-15	positive	mild	2	0
BIH-c-CoV-12	m	11-15	positive	moderate	9	0
BIH-c-CoV-13	m	11-15	positive	mild	3	2
BIH-c-CoV-14	m	16-20	positive	moderate	2	2
BIH-c-CoV-15	f	16-20	positive	mild	5	4
BIH-c-CoV-16	f	16-20	positive	mild	3	0
BIH-c-CoV-17	m	1-5	positive	moderate	3	4
BIH-c-CoV-18	m	1-5	positive	moderate	0	4
BIH-c-CoV-19	f	1-5	positive	mild	6	3
BIH-c-CoV-20	f	6-10	positive	mild	6	6
BIH-c-CoV-21	m	6-10	positive	mild	5	0
BIH-c-CoV-22	f	6-10	positive	mild	5	0
BIH-c-CoV-23	f	11-15	positive	moderate	2	8
BIH-c-CoV-24	m	11-15	positive	moderate	6	7
BIH-a-CoV-01	f	26-30	positive	moderate	2	2
BIH-a-CoV-02	f	26-30	positive	mild	6	0
BIH-a-CoV-03	f	31-35	positive	mild	4	0
BIH-a-CoV-04	f	31-35	positive	mild	8	0
BIH-a-CoV-05	f	31-35	positive	moderate	5	3
BIH-a-CoV-06	m	31-35	positive	moderate	0	0
BIH-a-CoV-07	f	36-40	positive	moderate	12	0
BIH-a-CoV-08	f	41-45	positive	moderate	10	7
BIH-a-CoV-09	f	41-45	positive	moderate	4	6
BIH-a-CoV-10	m	41-45	positive	moderate	11	2
BIH-a-CoV-11	m	46-50	positive	moderate	11	0
BIH-a-CoV-12	f	46-50	positive	moderate	10	3
BIH-a-CoV-13	m	46-50	positive	mild	3	6
BIH-a-CoV-14	f	31-35	positive	mild	2	0
BIH-a-CoV-15	m	31-35	positive	mild	0	1
BIH-a-CoV-16	m	31-35	positive	mild	0	0
BIH-a-CoV-17	f	36-40	positive	mild	4	0
BIH-a-CoV-18	f	36-40	positive	mild	2	0
BIH-a-CoV-19	m	76-80	positive	moderate	3	1
BIH-a-CoV-20	m	46-50	positive	mild	4	0
BIH-a-CoV-21	m	41-45	positive	moderate	3	7

*days post onset of symptoms; #days post first positive PCR

Supplementary Table 1: Continued.

(b)

Patient-ID	Gender	Age (years)	SARS-CoV-2	WHO	Sampling dps*
BIH-c-Con-01	f	1-5	negative	negative	no symptoms
BIH-c-Con-02	m	1-5	negative	negative	no symptoms
BIH-c-Con-03	f	1-5	negative	negative	no symptoms
BIH-c-Con-04	f	1-5	negative	negative	no symptoms
BIH-c-Con-05	m	6-10	negative	negative	no symptoms
BIH-c-Con-06	f	6-10	negative	negative	no symptoms
BIH-c-Con-07	m	6-10	negative	negative	no symptoms
BIH-c-Con-08	m	6-10	negative	negative	no symptoms
BIH-c-Con-09	m	6-10	negative	negative	no symptoms
BIH-c-Con-10	f	6-10	negative	negative	no symptoms
BIH-c-Con-11	f	6-10	negative	negative	no symptoms
BIH-c-Con-12	m	6-10	negative	negative	no symptoms
BIH-c-Con-13	f	6-10	negative	negative	no symptoms
BIH-c-Con-14	m	11-15	negative	negative	no symptoms
BIH-c-Con-15	m	11-15	negative	negative	no symptoms
BIH-c-Con-16	f	11-15	negative	negative	no symptoms
BIH-c-Con-17	m	11-15	negative	negative	no symptoms
BIH-c-Con-18	m	16-20	negative	negative	no symptoms
BIH-a-Con-01	m	21-25	negative	negative	no symptoms
BIH-a-Con-02	m	26-30	negative	negative	no symptoms
BIH-a-Con-03	f	26-30	negative	negative	no symptoms
BIH-a-Con-04	m	26-30	negative	negative	no symptoms
BIH-a-Con-05	f	26-30	negative	negative	no symptoms
BIH-a-Con-06	m	31-35	negative	negative	no symptoms
BIH-a-Con-07	f	31-35	negative	negative	no symptoms
BIH-a-Con-08	f	36-40	negative	negative	no symptoms
BIH-a-Con-09	m	36-40	negative	negative	no symptoms
BIH-a-Con-10	f	41-45	negative	negative	no symptoms
BIH-a-Con-11	f	41-45	negative	negative	no symptoms
BIH-a-Con-12	m	46-50	negative	negative	no symptoms
BIH-a-Con-13	f	46-50	negative	negative	no symptoms
BIH-a-Con-14	f	46-50	negative	negative	no symptoms
BIH-a-Con-15	f	61-65	negative	negative	no symptoms
BIH-a-Con-16	f	61-65	negative	negative	no symptoms
BIH-a-Con-17	m	61-65	negative	negative	no symptoms
BIH-a-Con-18	f	66-70	negative	negative	no symptoms
BIH-a-Con-19	f	66-70	negative	negative	no symptoms
BIH-a-Con-20	m	61-65	negative	negative	no symptoms
BIH-a-Con-21	f	61-65	negative	negative	no symptoms
BIH-a-Con-22	m	76-80	negative	negative	no symptoms
BIH-a-Con-23	m	55-60	negative	negative	no symptoms

*days post onset of symptoms

Supplementary Table 2: Summary of cohort characteristics.

	SARS-CoV-2 negative	SARS-CoV-2 positive
children		
female	8	10
male	10	14
0-6 years	4	7
7-10 years	9	7
11-18 years	5	10
median age (years)	9.0 ± 3.8	9.0 ± 5.6
mean dps* (days)	-	4.5 ± 2.8
mean dpP# (days)	-	2.2 ± 2.5
adults		
female	13	12
male	10	9
median age (years)	46.0 ± 16.3	39.0 ± 10.4
mean dps* (days)	-	5.0 ± 3.7
mean dpP# (days)	-	1.8 ± 2.5

*days post onset of symptoms, #days post first positive PCR test